2022
DOI: 10.1002/pd.6285
|View full text |Cite
|
Sign up to set email alerts
|

The inequity of targeted cystic fibrosis reproductive carrier screening tests in Australia

Abstract: Objective European and Australian guidelines for cystic fibrosis (CF) reproductive carrier screening recommend testing a small number of high frequency CF causing variants, rather than comprehensive CFTR sequencing. The study objective was to determine variant detection rates of commercially available targeted reproductive carrier screening tests in Australia. Methods Next‐generation DNA sequencing of the CFTR gene was performed on 2552 individuals from a whole population sample to identify CF causing variants… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 14 publications
(26 reference statements)
0
1
0
Order By: Relevance
“…Carrier screening with CFTR genetic panels tests for a small number of high-frequency pathogenic cystic fibrosis variants. Antenatal genetic screening is not immune to inequities, as previously noted in observations of the selection of newborn screening genetic panels . Clinicians involved in prenatal screening and family planning should consider limitations of antenatal detection from a narrow subset of CFTR pathogenic variants and discuss a role for more comprehensive testing for pan-ethnic carrier screening to address potential inequities…”
mentioning
confidence: 97%
“…Carrier screening with CFTR genetic panels tests for a small number of high-frequency pathogenic cystic fibrosis variants. Antenatal genetic screening is not immune to inequities, as previously noted in observations of the selection of newborn screening genetic panels . Clinicians involved in prenatal screening and family planning should consider limitations of antenatal detection from a narrow subset of CFTR pathogenic variants and discuss a role for more comprehensive testing for pan-ethnic carrier screening to address potential inequities…”
mentioning
confidence: 97%